Table 2 Comparison of demographic and baseline clinical characteristics of patients with schizophrenia in the trial of switching to aripiprazole between rebound and no rebound in positive subscores (N = 63)

Male, n (%)

9 (42.86)

17 (40.48)

0.86

Age, years, (SD)

41.8 (10.60)

37.1 (11.44)

0.14

Body height, cm, mean (SD)

161.5 (7.19)

162.7 (9.61)

0.70

Body weight, kg, mean (SD)

68.4 (11.35)

65.8 (12.29)

0.52

Age of onset, years, mean (SD)^b

26.6 (9.04)

28.2 (8.75)

0.30

Early age of onset, n (%) ^b

2 (9.52)

6 (14.29)

0.71

Late dropout, n (%)

4 (19.05)

6 (14.29)

0.25

Prolactin level at baseline, ng/dL, mean (SD)

47.6 (69.48)

55.6 (57.63)

0.15

Positive subscore in PANSS at baseline, mean (SD)^c

12.2 (4.41)

9.4 (4.26)

0.01*

Switching strategy in a previous trial, n (%)

0.72

 Fast strategy

10 (47.62)

22 (52.38)

 Slow strategy

11 (52.38)

20 (47.62)

Preswitching medication

0.04*

 First generation antipsychotics, n (%)

12 (57.14)

13 (30.95)

 Second generation antipsychotics, n (%)

9 (42.86)

29 (69.05)

 Chlorpromazine equivalent dose, mean (SD)

321.4 (198.20)

272.8 (247.60)

0.27